Johns Hopkins ABX Guide
Vilobelimab
INDICATIONS
FDA
FDA
- The FDA issued an Emergency Use and Authorization (EUA) permitting the use of vilobelimab for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults (>18 years of age) when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 3, 2023
Citation
Dzintars, Kathryn. "Vilobelimab." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540781/0.0/Vilobelimab.
Dzintars K. Vilobelimab. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540781/0.0/Vilobelimab. Accessed April 28, 2024.
Dzintars, K. (2023). Vilobelimab. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540781/0.0/Vilobelimab
Dzintars K. Vilobelimab [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 April 28]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540781/0.0/Vilobelimab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Vilobelimab
ID - 540781
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2023/09/03/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540781/0.0/Vilobelimab
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
